Browsing Tag
Regeneron Pharmaceuticals
36 posts
Regeneron earnings surge as Dupixent sales hit $6.5bn and Sanofi expands partnership
Regeneron revenue jumps 36% to $5.1 billion as Dupixent sales surge and Sanofi expands its partnership. Explore the earnings outlook.
Aclaris Therapeutics prices $50m share offering following positive ATI-052 trial results
Aclaris Therapeutics targets $50M financing after ATI-052 trial success. Explore its cash position, dilution risks and Phase 2b strategy.
Sanofi pays $1bn upfront in Regeneron alliance worth up to $8bn
Sanofi and Regeneron Pharmaceuticals have reset their two-decade immunology alliance with four long-acting antibody programmes, a $1 billion upfront payment and as much as $7 billion of future milestones as Sanofi prepares for the eventual erosion of Dupixent exclusivity.
REGN rises 3.8% as Pasatru opens a new rare-disease franchise for Regeneron
Pasatru wins FDA approval after cutting new FOP lesions 90%, expanding Regeneron’s rare-disease portfolio as pediatric development approaches.
Telix Pharmaceuticals (ASX: TLX) revenue tops $247m as pipeline spending rises
Telix Pharmaceuticals revenue is accelerating, but rising R&D spending and FDA decisions will determine whether ASX: TLX can regain its premium.
Is the gMG treatment race entering a lower-burden dosing phase?
Find out how Regeneron’s cemdisiran review could reshape generalized myasthenia gravis treatment, REGN stock sentiment and siRNA competition today!
Is Parabilis Medicines’ $670m Nasdaq IPO a biotech comeback signal or a high-risk oncology wager?
Find out how Parabilis Medicines’ upsized Nasdaq IPO reshapes biotech financing, Regeneron validation and investor appetite for Helicon platform drugs now.
Regeneron Pharmaceuticals’ LAG-3 gamble stumbles as Keytruda remains hard to beat in melanoma
Regeneron showed a PFS signal but missed the statistical bar. Keytruda remains the oncology benchmark investors still have to beat.
Regeneron Pharmaceuticals (NASDAQ: REGN) bets on data scale as TriNetX deal opens access to 300 million patient records
Regeneron is pairing with TriNetX to expand its health data reach and AI drug discovery ambitions. Read what the deal could change next.
Why Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) just strengthened the Eylea HD case against Roche’s Vabysmo
Regeneron won FDA approval for every-20-week Eylea HD dosing in wet AMD and DME. Read what it means for Regeneron, rivals, and retinal drug markets.